it is concerning uh with respect to legislation like that in terms of what it could potentially mean not just for Johnson and Johnson but for the industry of Life Sciences here in the US uh with respect to Innovation uh the industry is doing great things these days we’re hearing about obesity drugs we think about how companies came to really the rescue during the pandemic um we’re doing great things in oncology and Immunology and Neuroscience I’m not worried shortterm we’re going to continue to pursue the path we’ve got a stable of products that will um off set any of the losses that we have for maybe a few of the products that are subject to that new uh regulation